A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
Authors
Keywords
-
Journal
Journal of Neurodevelopmental Disorders
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-11-26
DOI
10.1186/s11689-022-09466-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]
- (2021) Elizabeth Merikle et al. BIOLOGICAL PSYCHIATRY
- ST1 Caregiver-Perceived Behavioral Challenges in Fragile X Syndrome (FXS) and Their Measurement Using the Aberrant Behavior Checklist-Community FXS Specific (ABC-CFXS)
- (2021) E. Merikle et al. VALUE IN HEALTH
- Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions
- (2020) Kyoungmi Kim et al. PLoS One
- Elevated FMR1-mRNA and lowered FMRP – A double-hit mechanism for psychiatric features in men with FMR1 premutations
- (2020) Andrea Schneider et al. Translational Psychiatry
- A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments
- (2020) Dejan B. Budimirovic et al. Brain Sciences
- A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
- (2019) Helen Heussler et al. Journal of Neurodevelopmental Disorders
- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
- (2018) Philip McGuire et al. AMERICAN JOURNAL OF PSYCHIATRY
- Sex differences and the neurobiology of affective disorders
- (2018) David R. Rubinow et al. NEUROPSYCHOPHARMACOLOGY
- Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
- (2018) Orrin Devinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Size and methylation mosaicism in males with Fragile X syndrome
- (2017) Poonnada Jiraanont et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
- (2017) Dejan B. Budimirovic et al. Journal of Neurodevelopmental Disorders
- Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective
- (2017) Ziva D Cooper et al. NEUROPSYCHOPHARMACOLOGY
- Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
- (2017) Orrin Devinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors
- (2017) T. Bakas et al. PHARMACOLOGICAL RESEARCH
- Fragile X syndrome
- (2017) Randi J. Hagerman et al. Nature Reviews Disease Primers
- Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
- (2015) John M McPartland et al. BRITISH JOURNAL OF PHARMACOLOGY
- Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
- (2015) Matthew W. Elmes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Endocannabinoid-mediated retrograde modulation of synaptic transmission
- (2014) Takako Ohno-Shosaku et al. CURRENT OPINION IN NEUROBIOLOGY
- Type 1 Cannabinoid Receptor Ligands Display Functional Selectivity in a Cell Culture Model of Striatal Medium Spiny Projection Neurons
- (2014) Robert B. Laprairie et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical and molecular implications of mosaicism in FMR1 full mutations
- (2014) Dalyir Pretto et al. Frontiers in Genetics
- Repeat-mediated genetic and epigenetic changes at the FMR1 locus in the Fragile X-related disorders
- (2014) Karen Usdin et al. Frontiers in Genetics
- Targeting the endocannabinoid system in the treatment of fragile X syndrome
- (2013) Arnau Busquets-Garcia et al. NATURE MEDICINE
- The translation of translational control by FMRP: therapeutic targets for FXS
- (2013) Jennifer C Darnell et al. NATURE NEUROSCIENCE
- Fragile X mental retardation protein and synaptic plasticity
- (2013) Michael S Sidorov et al. Molecular Brain
- Endocannabinoid Signaling and Synaptic Function
- (2012) Pablo E. Castillo et al. NEURON
- The evolution and comparative neurobiology of endocannabinoid signalling
- (2012) M. R. Elphick PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling
- (2012) M. Reisenberg et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome
- (2012) Kwang-Mook Jung et al. Nature Communications
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- (2012) F M Leweke et al. Translational Psychiatry
- The Psychiatric Presentation of Fragile X: Evolution of the Diagnosis and Treatment of the Psychiatric Comorbidities of Fragile X Syndrome
- (2011) Michael R. Tranfaglia DEVELOPMENTAL NEUROSCIENCE
- Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056
- (2011) S. Jacquemont et al. Science Translational Medicine
- A Novel FMR1 PCR Method for the Routine Detection of Low Abundance Expanded Alleles and Full Mutations in Fragile X Syndrome
- (2010) S. Filipovic-Sadic et al. CLINICAL CHEMISTRY
- Incidence of Fragile X Syndrome by Newborn Screening for Methylated FMR1 DNA
- (2009) Bradford Coffee et al. AMERICAN JOURNAL OF HUMAN GENETICS
- 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells
- (2008) Susanne Kreutz et al. GLIA
- FAAH and anandamide: is 2-AG really the odd one out?
- (2008) Vincenzo Di Marzo et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin
- (2007) R G Pertwee BRITISH JOURNAL OF PHARMACOLOGY
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
- (2007) A Thomas et al. BRITISH JOURNAL OF PHARMACOLOGY
- A Rapid Polymerase Chain Reaction-Based Screening Method for Identification of All Expanded Alleles of the Fragile X (FMR1) Gene in Newborn and High-Risk Populations
- (2007) Flora Tassone et al. JOURNAL OF MOLECULAR DIAGNOSTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started